Research News   |   Drug News   |   Conference News


Pfizer Buys FoldRx for Rare Disease Division
September 1, 2010


Neurotech Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial
August 30, 2010


Neuralstem Files FDA Application for First Chronic Spinal Cord Injury Stem Cell Trial
August 25, 2010
Neuralstem, a biotech company with a patent on producing neural stem cells, is seeking approval from the FDA to launch a Phase 1 safety clinical trial aimed at using stem cells to treat spinal cord injuries. The application was born in part out of lessons learned from the ongoing Neuralstem clinical trial involving transplanting stem cells into six ALS patients.


PatientsLikeMe Lands $8M
August 19, 2010
PatientsLikeMe, a Cambridge-based firm that creates online communities for individuals with particular illnesses, has raised $8M of a planned $30M. The firm generates revenue by selling anonymous health data provided by its users. PatientsLikeMe was founded by the Heywood family as a way to provide patients with access to tools and information about their disease after Stephen Heywood was diagnosed with ALS in 1998.


Biogen Agrees To Develop Knopp's Experimental ALS Drug
August 18, 2010
Biogen has partnered with Knopp Neurosciences to push forward the development of dexpramipexole, a drug which has shown promise in preserving motor function and extending survival of ALS patients. The deal for control of the orphan drug included a stock purchase, a cash payment, and incentives valued at roughly $345 million.